先健科技(01302.HK)Xuper™獲CE認證批准
格隆匯5月25日丨先健科技(01302.HK)宣佈,生效於2021年5月20日,集團自主研發的XuperTM主動脈術中覆膜支架系統已獲授歐洲的CE認證批准,該器械適用於Stanford A型主動脈夾層患者的雜交手術治療。
XuperTM由主動脈術中支架及其對應的輸送系統組成。主動脈術中支架為獨特的帶分支結構,分支的角度和間距可調節且自適應血管形態;近端三層結構設計,更便於手術鉗夾持並與支架近端吻合。與當前雜交手術中使用無分支支架結構的支架產品相比,XuperTM能顯着減少手術中吻合口的數量,縮短了深低温停循環時間,減少了術後併發症及術中死亡率;同時縮短了學習曲線,更便於術式的推廣。
集團將繼續堅持自主創新,攜手業內專家推進創新醫療器械產品的研發和上市進程,造福廣大患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.